Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Therapy Clear all
Not yet recruiting Phase 3 Interventional

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

NCT07285798
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 17 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
23
States / cities
Phoenix, Arizona • Glendale, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 3, 2026, 11:27 PM EDT
Active, not recruiting Not applicable Interventional

Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health

NCT06065098
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension, Diabetes, Hypercholesterolemia
Interventions
Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
40 Years and older
Enrollment
812 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 3, 2026, 11:27 PM EDT
Terminated Early Phase 1 Interventional

Neostigmine For Snoring During DISE

NCT03316963
View directory record Official record
Conditions
Snoring
Interventions
Neostigmine Methylsulfate
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Not applicable Interventional Results available

Safety Study of Quickclot for Bleeding Control After Adenotonsillectomy

NCT01863563
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
QuickClot
Device
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Not applicable Interventional Results available

Helping Empower Liver and Kidney Patients

NCT03426787
View directory record Official record
Conditions
Hepatitis C, Chronic Kidney Diseases, Patient Education
Interventions
Decision Aid
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Not applicable Interventional

Usefulness of Acupuncture in Cancer Pain and Quality of Life

NCT00401063
View directory record Official record
Conditions
Cancer, Pain
Interventions
Acupuncture
Device
Lead sponsor
Southern California University of Health Sciences
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Pasadena, California • Whittier, California
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Sep 3, 2026, 11:27 PM EDT
Recruiting Not applicable Interventional

IHT for Mild Cognitive Impairment

NCT05495087
View directory record Official record
Conditions
Mild Cognitive Impairment, Memory Impairment
Interventions
IHT Treatment, Sham-IHT Control
Device · Other
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
55 Years to 79 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes

NCT00118287
View directory record Official record
Conditions
de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
Interventions
azacitidine, etanercept
Drug · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Not applicable Interventional

Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder

NCT02990793
View directory record Official record
Conditions
PostTraumatic Stress Disorder, Traumatic Brain Injury, Postconcussive Symptoms
Interventions
Active MeRT Treatment, Sham MeRT Treatment
Device
Lead sponsor
Wave Neuroscience
Industry
Eligibility
18 Years to 65 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Costa Mesa, California • Long Beach, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 3, 2026, 11:27 PM EDT
Terminated Not applicable Interventional Results available

Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks

NCT00329732
View directory record Official record
Conditions
Migraine
Interventions
0.5% bupivicaine and 2% lidocaine, Saline placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Sep 3, 2026, 11:27 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

NCT02132598
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain
Interventions
cabozantinib
Drug
Lead sponsor
Liza Villaruz, MD
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Phase 3 Interventional Results available

Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation

NCT01898221
View directory record Official record
Conditions
Ventricular Tachycardia, Atrial Fibrillation
Interventions
Ethanol, Ablation
Drug · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies

NCT02094716
View directory record Official record
Conditions
Scabies
Interventions
Permethrin Foam 4%, Permethrin Foam 5%, Vehicle Foam
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
6 Months and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Fremont, California • Los Angeles, California • Hialeah, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Not applicable Interventional Results available

PRogram In Support of Moms: An Innovative Stepped-Care Approach for Obstetrics and Gynecology Clinics

NCT02760004
View directory record Official record
Conditions
Depression
Interventions
PRogram In Support of Moms (PRISM), MCPAP for Moms
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2024 · Synced Sep 3, 2026, 11:27 PM EDT
Terminated Phase 4 Interventional Results available

Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)

NCT05228184
View directory record Official record
Conditions
Congenital Hypothyroidism
Interventions
Tirosint®-SOL, Levothyroxine Sodium
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
1 Day to 9 Months
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Disability Via a Bundled Bio-Behavioral-Environmental Approach

NCT01576133
View directory record Official record
Conditions
Quality of Life
Interventions
CAPABLE, Attention visits
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

NCT01998984
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ingenol mebutate, Placebo
Drug · Other
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 3, 2026, 11:27 PM EDT
Not listed No phase listed Observational

Evaluation of the Optimal Transition Program

NCT04263233
View directory record Official record
Conditions
ESRD, Hemodialysis
Interventions
Analysis using descriptive statistics of patient clinical outcomes., Surveys with participants using validated survey tools., Evaluation of the program process including time, costs, referral rates, admission to the program and length of stay.
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Oakland, California • Sacramento, California • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 3, 2026, 11:27 PM EDT
Terminated Phase 2 Interventional Results available

Multi-catheter High Dose Rate (HDR) Breast Brachytherapy

NCT00214149
View directory record Official record
Conditions
Breast Cancer
Interventions
brachytherapy
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Phase 1 Interventional

Carboxyamidotriazole and Ketoconazole in Treating Patients With Advanced Cancers

NCT00003249
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboxyamidotriazole, chemotherapy, ketoconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility Study of a Multi-Component Intervention for Black Men Who Have Sex With Men

NCT00951249
View directory record Official record
Conditions
HIV Infections
Interventions
Referral of Partners, Screening for STIs and counseling, Peer health care system navigators, Enhanced counseling
Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,553 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Phase 3 Interventional

Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

NCT00002649
View directory record Official record
Conditions
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Interventions
aldesleukin, filgrastim, cyclophosphamide, etoposide, radiation therapy, peripheral blood stem cell transplantation, bone marrow ablation with stem cell support
Biological · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 60 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Phase 3 Interventional Results available

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy

NCT00451958
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix 80 mg / Degarelix 80 mg, Degarelix 160 mg / Degarelix 160 mg, Leuprolide 7.5 mg / Degarelix 80 mg, Leuprolide 7.5 mg / Degarelix 160 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Homewood, Alabama • Laguna Hills, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 3, 2026, 11:27 PM EDT
Completed Phase 2 Interventional

Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)

NCT02794155
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HDV Insulin Lispro, Insulin LISPRO
Drug
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Corona, California • Los Angeles, California • Northridge, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 3, 2026, 11:27 PM EDT